Newer Anti-Seizure Medications (Brivaracetam, Cenobamate)

Introduction And Clinical Rationale

Pediatric epilepsy affects approximately 1 in 100 children, with Drug-Resistant Epilepsy (DRE) occurring in 20-30% of cases.
Traditional ASDs frequently fail in focal or genetic epilepsies and cause dose-limiting sedation or behavioral worsening.
Newer ASDs, specifically Brivaracetam and Cenobamate, offer targeted mechanisms, superior efficacy in focal DRE, and simplified dosing regimens to reduce polytherapy side effects.

Functions as a high-affinity synaptic vesicle protein 2A (SV2A) ligand.
Exhibits significantly higher selectivity for SV2A compared to levetiracetam (LEV), reducing off-target psychiatric adverse events.

Meta-analyses confirm responder rates >50% and seizure freedom rates of 20-40% when used as monotherapy or adjunctive therapy.
Switching patients from LEV to BRV actively improves behavioral profiles and seizure control.
Real-world pediatric cohorts report very low discontinuation rates (<12%) for behavioral issues.
Common adverse effects include mild somnolence and dizziness.

AES Guidelines (2026): Conditionally suggests BRV for DRE in infants aged 1 month to <36 months.
IAP Guidelines (2025–2026): Endorses BRV as adjunctive therapy for focal seizures in children $\geq$ 2 years of age.

Real-world pediatric studies (2025–2026) in DRE (including developmental and epileptic encephalopathies like Lennox-Gastaut) demonstrate 50-84% responder rates and 3-31% absolute seizure freedom.
Off-label utilization in children <18 years achieved an 80% median seizure reduction and allowed for ASM regimen simplification (e.g., reducing from 5 to 2 concurrent drugs).
Superior efficacy compared to brivaracetam, lacosamide, and perampanel in focal epilepsy.
Adverse effects include somnolence and behavioral changes, mandating routine monitoring for suicidality.
Caution is advised in Dravet syndrome due to possible seizure worsening.

NICE Guidelines (2025): Included for refractory focal epilepsy, with pediatric extrapolation supported by 2026 adolescent pharmacokinetic data confirming adult-comparable exposures.
IAP Guidelines (2025–2026): Emerging as an option for refractory focal DRE in adolescents.

Parameter	Brivaracetam (BRV)	Cenobamate
Primary Target	SV2A ligand	GABA enhancement + Sodium-channel modulation
Key Advantage	High behavioral tolerability; replaces LEV	Superior efficacy in refractory focal DRE; dual mechanism
Pediatric Age Approval	$\geq$ 2 years (IAP), 1 to <36 months for DRE (AES)	Adolescents (off-label pediatric pathways emerging)
Adverse Effects	Somnolence, dizziness	Somnolence, behavioral changes, suicidality risk